Torrent Gets FDA Warning Letter
Comprehensive Review Of Global Manufacturing Operations Needed
Executive Summary
Torrent has been told to conduct a comprehensive review of its global manufacturing operations by the US Food and Drug Administration, as the agency sent a warning letter to the Indian firm over its local manufacturing facility in Indrad, Gujarat.
You may also be interested in...
Regulatory Overhang Hurts Torrent
Torrent has tempered US growth expectations while it plans to put its Dahej, Indrad and Levittown plants up for FDA inspection in 2020. Meanwhile, products launched in India, including remoglifozin in-licensed from Glenmark, have shown an encouraging uptake.
India 2019 – R&D Highs, Compliance Woes And Other Lows
2019 saw Indian companies advance innovation efforts and build and expand their specialty portfolios and biosimilars businesses. But manufacturing compliance issues weighed down several firms while on another front charges against the Singh brothers of Ranbaxy escalated.
India 2019 – R&D Highs, Compliance Woes And Other Lows
2019 saw Indian companies advance innovation efforts and build and expand their specialty portfolios and biosimilars businesses. But manufacturing compliance issues weighed down several firms while on another front charges against the Singh brothers of Ranbaxy escalated.